News & Analysis on Clinical Trial Services & Contract Research And Development
The European Commission has granted Orphan Medicinal Product designation for zatolmilast an investigational treatment for Fragile X syndrome (FXS), a leading cause of inherited intellectual disability and autism.
Yesterday's migraine treatment breakthrough, though amidst a complex journey to find a cure, still promises a dramatic impact despite the absence of a 'magic bullet.'
DCAT 2024
In the fast-paced domain of pharmaceutical contract development and manufacturing organizations (CDMOs), Selkirk Pharma believes it stands out as a beacon of innovation and reliability.